A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
暂无分享,去创建一个
Stefan Schreiber | Ali Keshavarzian | A. Keshavarzian | S. Hanauer | C. Orlandi | Stephen B Hanauer | Kim L Isaacs | John Schollenberger | Juan P Guzman | Cesare Orlandi | K. Isaacs | S. Schreiber | J. Guzman | J. Schollenberger
[1] S. Nikolaus,et al. Placebo Response in the Therapy of Crohn's Disease: A Comprehensive Analysis of Primary Data From 733 Patients From 13 Randomized, Controlled Trials , 2006 .
[2] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[3] A. Michalsen,et al. Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[4] Kam Y. J. Zhang,et al. Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.
[5] D. Spina,et al. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation. , 2005, Current opinion in investigational drugs.
[6] S. Schreiber,et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.
[7] Mario Albrecht,et al. Genetics of Crohn disease, an archetypal inflammatory barrier disease , 2005, Nature Reviews Genetics.
[8] S. Friedman. General principles of medical therapy of inflammatory bowel disease. , 2004, Gastroenterology clinics of North America.
[9] C. Brensinger,et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. , 2004, Gastroenterology.
[10] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[11] A. Cross,et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.
[12] P. Dagnelie,et al. The Impact of Inflammatory Bowel Disease on Labor Force Participation: Results of a Population Sampled Case-Control Study , 2002, Inflammatory bowel diseases.
[13] M. Grisham,et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. , 2002, Free radical biology & medicine.
[14] M. Stolte,et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.
[15] S. Hanauer,et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.
[16] J. Upward,et al. An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers , 2001, Journal of clinical pharmacology.
[17] T. Hinterleitner,et al. Mesalazine 4 g Daily Given as Prolonged-Release Granules Twice Daily and Four Times Daily Is at Least as Effective as Prolonged-Release Tablets Four Times Daily in Patients with Ulcerative Colitis , 2001, Inflammatory bowel diseases.
[18] E. Hahn,et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. , 2001, Gastroenterology.
[19] A. Keshavarzian,et al. OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. , 2001, Free radical biology & medicine.
[20] P. Usai,et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double‐blind, double‐dummy, randomized multicentre study , 2001, Alimentary pharmacology & therapeutics.
[21] C. Fiocchi. Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.
[22] S. Nikolaus,et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation , 1998, Gut.
[23] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[24] B. Feagan,et al. Does self-administration of a quality of life index for inflammatory bowel disease change the results? , 1996, Journal of clinical epidemiology.
[25] G. Strassmann,et al. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. , 1995, Journal of immunology.
[26] M. Tominaga,et al. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.
[27] R. Macdermott. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. , 1994, The Medical clinics of North America.
[28] P. Munkholm,et al. Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.
[29] A. Keshavarzian,et al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. , 1993, Gut.
[30] S. Hanauer,et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.
[31] A. Keshavarzian,et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. , 1992, Gastroenterology.
[32] J. Kirsner. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. , 1991, Disease-a-month : DM.
[33] S. Lo,et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.
[34] K. Matsumoto,et al. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. , 1989, Digestion.
[35] G. Guyatt,et al. A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.
[36] Ami,et al. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.
[37] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[38] S. Truelove. Ulcerative colitis beginning in childhood. , 1971, The New England journal of medicine.
[39] A. Lobo,et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. , 1998, Gastroenterology.
[40] R. Greenberg. Overview of patient compliance with medication dosing: a literature review. , 1984, Clinical therapeutics.